UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 60

Sortiert nach

TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis

Advances in therapy, 2023-04, Vol.40 (4), p.1317-1333

2023

Link zum Volltext

Verfügbarkeit prüfen

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

The lancet. Diabetes & endocrinology, 2018-09, Vol.6 (9), p.691-704

2018

Link zum Volltext

Verfügbarkeit prüfen

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Circulation (New York, N.Y.), 2018-07, Vol.138 (5), p.458-468

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Circulation (New York, N.Y.), 2019-05, Vol.139 (22), p.2591-2593

2019

Link zum Volltext

Verfügbarkeit prüfen

Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2

ACS omega, 2019-04, Vol.4 (4), p.6703-6708

2019

Link zum Volltext

Verfügbarkeit prüfen

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

Circulation (New York, N.Y.), 2001-08, Vol.104 (7), p.820-825

2001

Link zum Volltext

Verfügbarkeit prüfen

Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis

American journal of physiology. Heart and circulatory physiology, 2008-01, Vol.294 (1), p.H145-H155

2008

Link zum Volltext

Verfügbarkeit prüfen

C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion

The Journal of pharmacology and experimental therapeutics, 2002-12, Vol.303 (3), p.1007

2002

Link zum Volltext

Verfügbarkeit prüfen

Obestatin reduces food intake and suppresses body weight gain in rodents

Biochemical and biophysical research communications, 2007-05, Vol.357 (1), p.264-269

2007

Link zum Volltext

Verfügbarkeit prüfen

Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer

Trends in pharmacological sciences (Regular ed.), 2011-04, Vol.32 (4), p.201-205

2011

Link zum Volltext

Verfügbarkeit prüfen

Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation‐induced anaemia in rats

British journal of pharmacology, 2015-08, Vol.172 (16), p.4078-4088

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction

Hematology (Luxembourg), 2020-01, Vol.25 (1), p.112-117

2020

Link zum Volltext

Verfügbarkeit prüfen

Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel

The Journal of pharmacology and experimental therapeutics, 2004-05, Vol.309 (2), p.554

2004

Link zum Volltext

Verfügbarkeit prüfen

Pyrazole CCK1 receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity

Bioorganic & medicinal chemistry letters, 2006, Vol.16 (1), p.77-80

2006

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Biological Studies of Novel 2-Aminoalkylethers as Potential Antiarrhythmic Agents for the Conversion of Atrial Fibrillation

Journal of medicinal chemistry, 2007-06, Vol.50 (12), p.2818-2841

2007

Link zum Volltext

Verfügbarkeit prüfen

Characterization of a Robust Enzymatic Assay for Inhibitors of 2-Oxoglutarate-Dependent Hydroxylases

Journal of biomolecular screening, 2009-07, Vol.14 (6), p.627-635

2009

Link zum Volltext

Verfügbarkeit prüfen

3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide

The Journal of pharmacology and experimental therapeutics, 2007-11, Vol.323 (2), p.562

2007

Link zum Volltext

Verfügbarkeit prüfen

Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2α (HRI) kinase

Bioorganic & medicinal chemistry letters, 2009-12, Vol.19 (23), p.6548-6551

2009

Link zum Volltext

Verfügbarkeit prüfen

Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues

ACS medicinal chemistry letters, 2010-12, Vol.1 (9), p.526-529

2010

Link zum Volltext

Verfügbarkeit prüfen

Tedisamil and dofetilide‐induced torsades de pointes, rate and potassium dependence

British journal of pharmacology, 2001-04, Vol.132 (7), p.1493-1500

2001

Link zum Volltext

Verfügbarkeit prüfen

JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability

The Journal of pharmacology and experimental therapeutics, 2011-07, Vol.338 (1), p.328

2011

Link zum Volltext

Verfügbarkeit prüfen

Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: Tuning of receptor selectivity and in vivo efficacy

Bioorganic & medicinal chemistry letters, 2009-11, Vol.19 (22), p.6376-6378

2009

Link zum Volltext

Verfügbarkeit prüfen

SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists

Bioorganic & medicinal chemistry letters, 2007-12, Vol.17 (23), p.6493-6498

2007

Link zum Volltext

Verfügbarkeit prüfen

Mechanism of Tissue-Selective Drug Action in the Cardiovascular System

Molecular interventions, 2005-04, Vol.5 (2), p.84-93

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(59)
Buchkapitel
(1)

Sprache

Englisch
(60)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor

Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis

C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion

Obestatin reduces food intake and suppresses body weight gain in rodents

Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer

Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation‐induced anaemia in rats

Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction

Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel

Pyrazole CCK1 receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity

Synthesis and Biological Studies of Novel 2-Aminoalkylethers as Potential Antiarrhythmic Agents for the Conversion of Atrial Fibrillation

Characterization of a Robust Enzymatic Assay for Inhibitors of 2-Oxoglutarate-Dependent Hydroxylases

3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide

Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2α (HRI) kinase

Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues

Tedisamil and dofetilide‐induced torsades de pointes, rate and potassium dependence

JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability

Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: Tuning of receptor selectivity and in vivo efficacy

SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists

Mechanism of Tissue-Selective Drug Action in the Cardiovascular System

Suchergebnisse filtern